Over 25 years of experience in international business development in the pharma industry. Head of commercial operations and business development for BMS in 16 Latin American countries. Global management consultant. Speaks French and Spanish fluently. Completed many transactions in global markets in the past 15 years.
More than 25 years of experience in the biopharma industry. Global Head of BD (CBO) at Besins Healthcare (completed 15 deals in 3 years). CP BFD/AM at Avadel Pharmaceuticals and Director of BD at Micromet (now Amgen), to Crucell (now J&J), founding CEO of Avidis (now Imaxio/Osivax) and BoD Member-liquidator of Aptanomics. Binational PhD (France/Canada) and post-doctoral research at the Laboratory of Molecular Biology of the MRC (Cambridge, UK).
Over 7 years of experience in the pharma/biotech industry. Former Life Sciences management consultant for Navigant Consulting. Formely part of Financial Supply Group at Pfizer. Former Equity Research Associate in the Biotech Sector.
Over 14 years of strategic, commercial, and business development experience in the biopharma industry. Former Vice President of Business Development at Intrance Medical Systems, with prior business development leadership roles at Azurity and Arbor Pharmaceuticals. Experience includes licensing, product acquisitions, strategic partnering, commercialization, product launches, and corporate development across multiple therapeutic areas within specialty pharma. Former LPGA professional athlete and graduate of the University of North Carolina at Chapel Hill.
18 years of investment banking and private equity experience. Over 30 completed transactions totaling more than $9 billion across pharma M&A and capital solutions. Prior derivatives and structured finance experience at BB&T Capital Markets (now Truist Securities). Graduate of Wake Forest University.
Over 9 years of experience in finance and business operations, spanning multinational corporations and early-stage, high-growth companies where she has played a key role in building financial infrastructure from the ground up. Her educational background includes a BSc in Economics and a Postgraduate Degree in Marketing Management from ISEG – Lisbon School of Economics & Management, a Postgraduate Degree in Tax Law from Universidade Católica Portuguesa, and a Strategy specialization from Harvard Business School Online.
Founder of PharmaTheme. Served as CEO of LabourMed Pharma and of Terapia, an Advent company that was acquired and sold with an 11x multiple. Has managed the Central and Eastern Europe (CEE) and Commonwealth of Independent States (CIS) regions for Ranbaxy/Sun Pharma and held the position of Head of Global Business Development for STADA. Educational background includes a BPharm (Hons) from Nottingham University and management training at Ashridge and IMD management schools.
Over 25 years of experience spanning commercial strategy, operations and transformation-related leadership roles in MNCs and Biotech across the US, Europe and Emerging Markets. At BMS he was a US affiliate sales and held marketing roles and leadership roles in international markets. At Boehringer-Ingelheim, in Germany, he led a 300M emerging markets business. At Merck KGaA he led the commercial and access excellence function for general medicines and fertility franchises across Emerging Markets. Global Marketing Leader for Immunology at Galapagos. Arthur’s core areas of focus are US, European and Emerging Markets-wide commercial strategy, operations and transformation.
More than 25 years of experience in the pharmaceutical industry, mostly in Europe and in Asia-Pacific, including Japan. Held different leading positions in commercial operations and business development with Merck Serono, Allergan and Lupin. Has a wide network in the healthcare and investors community. Track record of more than 100 transactions closed – has developed extensive experience in all facets of strategy, business development, M&A, and Licensing at global, regional and local levels.
Served as Chief Medical Officer at Squibb Diagnostics, Bristol-Myers Squibb, Mallinckrodt, and Esperion Therapeutics. Co-founder of: CardioVax, VIA Pharmaceuticals, and EpiGen Pharmaceuticals. Part of the boards of Arrowhead Pharmaceuticals and Tonix Pharmaceuticals. CEO and part of the management team of Genesis Unicorn Capital Corp, a Special Purpose Acquisition Company (SPAC). Educational background includes a B.A im Chemistry from the University of North Carolina at Chapel Hill, an M.D. from Albert Einstein College of Medicine, and an MPH from Harvard University.
